Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Iovance Biotherapeutics, Inc. (IOVA)

4.43   -0.12 (-2.64%) 10-02 16:00
Open: 4.55 Pre. Close: 4.55
High: 4.59 Low: 4.365
Volume: 4,433,116 Market Cap: 1,098(M)

Technical analysis

as of: 2023-10-02 4:51:02 PM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 6.61     One year: 7.55
Support: Support1: 4.36    Support2: 3.62
Resistance: Resistance1: 5.66    Resistance2: 6.46
Pivot: 4.99
Moving Average: MA(5): 4.49     MA(20): 5.23
MA(100): 7.04     MA(250): 7.07
MACD: MACD(12,26): -0.6     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 7.2     %D(3): 7
RSI: RSI(14): 32.7
52-week: High: 10.4  Low: 4.36
Average Vol(K): 3-Month: 6,354 (K)  10-Days: 6,026 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IOVA ] has closed above bottom band by 22.5%. Bollinger Bands are 13.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.59 - 4.62 4.62 - 4.65
Low: 4.31 - 4.34 4.34 - 4.36
Close: 4.39 - 4.43 4.43 - 4.47

Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Headline News

Mon, 02 Oct 2023
Block Trade of 1 Million AUPH Shares at 7405 Per Share - Best Stocks

Mon, 02 Oct 2023
Premarket Mover: Iovance Biotherapeutics Inc (IOVA) Up 1.76% - InvestorsObserver

Wed, 27 Sep 2023
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for ... - GlobeNewswire

Fri, 22 Sep 2023
Iovance Biotherapeutics Reports Inducement Grants under ... - GlobeNewswire

Mon, 18 Sep 2023
Thinking about buying stock in Navios Maritime Holdings, Biodexa ... -

Mon, 18 Sep 2023
Alteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday’s Pre-Market Session - Alte - Benzinga

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 248 (M)
% Held by Insiders 2.0983e+008 (%)
% Held by Institutions 0.3 (%)
Shares Short 27,550 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.1738e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -179
Return on Assets (ttm) 988.6
Return on Equity (ttm) -39.2
Qtrly Rev. Growth 238000
Gross Profit (p.s.) 0
Sales Per Share -885.34
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -335 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0.1
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.15

Stock Dividends

Dividend 0
Forward Dividend 3.007e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.